EUCTR2020-000192-20-HU进行中（未招募）1 期
A Phase 4, multicenter study to evaluate the discontinuation and re treatment in subjects with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following criteria to be eligible for enrollment into the study:
- •1. Currently enrolled and have not been discontinued from pexidartinib treatment in one of the following studies: Study PLX108-10 (ENLIVEN), Study PLX108-01, Study PL3397-A-A103, or Study PL3397-A-U126.
- •2. Willing and able to complete the PROMIS (Physical Function Scale) and EQ-5D-5L (European Quality of Life) throughout the study.
- •3. Willing and able to provide written informed consent form (ICF) prior to any study-related procedures and to comply with all study requirements.
- •4. Females of reproductive potential must have a negative urine pregnancy test at Screening/Baseline (to be confirmed by a serum pregnancy test taken on the End-of-Treatment visit of their prior study) and should be advised to use an effective, non-hormonal method of contraception during treatment with pexidartinib and for 1 month after the last dose. Males with female partners of reproductive potential should be advised to use an effective method of contraception during treatment with pexidartinib and for 1 month after the last dose. Female partners of male patients should concurrently use effective contraceptive methods (hormonal or non-hormonal).
- •Note: A female is considered of reproductive potential following menarche and until becoming postmenopausal (no menstrual period for a minimum of 12 months) unless permanently sterile (undergone a hysterectomy, bilateral salpingectomy or bilateral oophorectomy) with a confirmed by follicle stimulating hormone (FSH) test level >40 mIU/mL.
- •5. Male subjects must not freeze or donate sperm starting at Screening and throughout the study period, and for at least 5 half-lives or 1 month after the final study drug administration, whichever is longer.
- •Female subjects must not donate, or retrieve for their own use, ova from the time of Screening and throughout the study treatment period, and for at least 1 month or 5 half-lives after the final study drug administration, whichever is longer.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 46
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •Subjects who meet any of the following criteria are NOT eligible for enrollment into the study
- •1. Subject has a clinically significant abnormality identified by the Investigator at Screening on physical examination, laboratory tests, or electrocardiogram which, in the judgement of the Investigator, would preclude the subject’s safe completion of the study.
- •2. Exposure to another investigational drug or current participation in other therapeutic investigational procedures, besides pexidartinib studies, within 1 month prior to start of study treatment. Any known contraindication to treatment with, including hypersensitivity to, the study drug(s) or excipients in pexidartinib.
研究者
相似试验
进行中（未招募）
1 期
A Phase 4, multicenter study to evaluate the discontinuation and re treatment in subjects with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinibTenosynovial giant cell tumor (TGCT) is a group of neoplasms including pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCT-TS)MedDRA version: 20.0Level: LLTClassification code 10062856Term: Giant cell tumour of tendon sheath benignSystem Organ Class: 100000004864EUCTR2020-000192-20-NLDAIICHI SANKYO, INC.32
进行中（未招募）
1 期
A Phase 4, multicenter study to evaluate the discontinuation and re treatment in subjects with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinibEUCTR2020-000192-20-ITDAIICHI SANKYO INC.49
已完成
4 期
A Phase 4, Multicenter Study to Evaluate Discontinuation and Re-Treatment in Subjects with Tenosynovial Giant Cell Tumor (TGCT) Previously Treated with PexidartinibNL-OMON52692DAIICHI SANKYO, INC.1
进行中（未招募）
不适用
Study to evaluate immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy Taiwanese infants who received hepatitis B immunoglobulin after birth.EUCTR2011-003731-63-Outside-EU/EEAGlaxoSmithKline Biologicals15
进行中（未招募）
不适用
An open, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children 4-6 years old, previously vaccinated with 4 doses of GlaxoSmithKline (GSK) Biologicals’ DTPa-HBV-IPV/Hib vaccine, in clinical trials conducted by GSK Biologicals. - DTPa-HBV-IPV-111Four dose vaccination course with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine, given as a three-dose primary vaccination series in the first year of life, followed by a booster in the second year of life: immune persistence and hepatitis B vaccine challenge at 4-6 years of age.EUCTR2006-000553-22-DEGlaxoSmithKline Biologicals300